Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.

Citation metadata

From: The New England Journal of Medicine(Vol. 381, Issue 26)
Publisher: Massachusetts Medical Society
Document Type: Report
Length: 51 words

Document controls

Main content

Abstract :

Cabazitaxel significantly improved a number of clinical outcomes, as compared with abiraterone or enzalutamide, in patients with metastatic castration-resistant prostate cancer. Imaging-based progression or death was reported in 95 of 129 patients in the cabazitaxel group, as compared with 101 of 126 patients in the group that received an androgen-signaling-targeted inhibitor.

Source Citation

Source Citation   

Gale Document Number: GALE|A617382029